Matthias Schneider
Overview
Explore the profile of Matthias Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
532
Citations
8500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider M, Potthoff A, Ahmadipour Y, Borger V, Clusmann H, Combs S, et al.
BMC Cancer
. 2025 Feb;
25(1):306.
PMID: 39979825
Background: The discovery of cellular tumor networks in glioblastoma, with routes of malignant communication extending far beyond the detectable tumor margins, has highlighted the potential of supramarginal resection strategies. Retrospective...
2.
Blunschi F, Gluding D, Hassdenteufel E, Schneider M, Lehmann H
Front Vet Sci
. 2025 Feb;
12:1465988.
PMID: 39968106
Background: Cell saver (CS) technology is an increasingly popular approach for autotransfusion in small animal veterinary medicine for the treatment of patients with abdominal hemorrhagic effusion. Objective: To evaluate the...
3.
Zeyen T, Weller J, Schneider M, Potthoff A, Schaub C, Roever L, et al.
Neurooncol Adv
. 2025 Feb;
7(1):vdaf005.
PMID: 39902392
Background: Polychemotherapy based on high-dose methotrexate (HD-MTX) is the standard therapy for newly diagnosed younger patients (<65 years) with primary CNS lymphoma (PCNSL). In the modified Bonn protocol, consolidation therapy...
4.
Luck A, Pu J, Melhem A, Schneider M, Sharma A, Schmidt-Wolf I, et al.
Sci Rep
. 2025 Jan;
15(1):734.
PMID: 39753685
Despite the favorable effects of immunotherapies in multiple types of cancers, its complete success in CNS malignancies remains challenging. Recently, a successful clinical trial of cytokine-induced killer (CIK) cell immunotherapy...
5.
Schmidt E, Evert B, Pregler B, Melhem A, Hsieh M, Raspe M, et al.
Mol Oncol
. 2024 Dec;
19(3):878-898.
PMID: 39680504
Glioblastoma cells rely on connexin 43 (Cx43)-based gap junctions (GJs) for intercellular communication, enabling them to integrate into a widely branched malignant network. Although there are promising prospects for new...
6.
Ramien R, Rudi T, Alten R, Krause A, Schneider M, Schaefer M, et al.
Arthritis Res Ther
. 2024 Dec;
26(1):209.
PMID: 39639378
Background: To investigate the association between the development of incident interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) and the disease activity of RA with its various components,...
7.
Dubinski D, Won S, Hardung C, Rafaelian A, Paschke K, Arsenovic M, et al.
World Neurosurg
. 2024 Nov;
194:123523.
PMID: 39615621
Objective: Although the operating theatre offers unique didactic opportunities, it can be perceived as an uncomfortable environment by medical students due to the lack of theatre etiquette, time pressure and...
8.
Shabo E, Potthoff A, Zeyen T, Layer J, Ehrentraut S, Scorzin J, et al.
J Neurooncol
. 2024 Nov;
171(3):681-689.
PMID: 39607570
Purpose: Prophylactic insertion of an external ventricular drainage (EVD) prior to the resection of posterior fossa metastases (PFMs) is a common approach to address postoperative transient and permanent hydrocephalus. However,...
9.
Weller J, Kocakavuk E, Pregler B, Zeyen T, Schafer N, Potthoff A, et al.
Neuro Oncol
. 2024 Nov;
27(1):306-308.
PMID: 39545540
No abstract available.
10.
Hansen H, Comoglio C, Elings J, Ericsson P, Goethals P, Gosselin M, et al.
Bioscience
. 2024 Oct;
74(9):624-639.
PMID: 39421009
Multiple anthropogenic forces have pushed river ecosystems into undesirable states with no clear understanding of how they should be best managed. The advancement of riverine fish habitat models intended to...